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Importance of quantitative genetic variations in the etiology trated in Figure 1, which is a reproduction from the
of hypertension. progress report of the Hypertension Detection and Fol-
Recent progress has been remarkable in identifying muta- low-up Program (HDFP) Cooperative Group of a compi-tions which cause diseases (mostly uncommon) that are inher-
lation of diastolic blood pressures measured mostly atited simply. Unfortunately, the common diseases of humankind
home in close to 160,000 persons aged 30 to 69 yearswith a strong genetic component, such as those affecting cardio-
vascular function, have proved less tractable. Their etiology is from 14 communities [1]. There were some deliberate
complex with substantial environmental components and biases in the choice of communities for inclusion in this
strong indications that multiple genes are implicated. In this
study, but the data speak for themselves: Blood pressuresarticle, we consider the genetic etiology of essential hyperten-
are distributed in the population in a continuous fashionsion. After presenting the distribution of blood pressures in
the population, we propose the hypothesis that essential hyper- with the exact incidence of “hypertension” being to a
tension is the consequence of different combinations of genetic substantial degree a matter of definition. Nevertheless,
variations that are individually of little consequence. The candi- there is general agreement that, as summarized by Pick-
date gene approach to finding relevant genes is exemplified by
ering [2], “the relationship between arterial pressure andstudies that identified potentially causative variations associ-
mortality is quantitative; the higher the pressure the worseated with quantitative differences in the expression of the an-
giotensinogen gene (AGT). Experiments to test causation di- the prognosis.” However, it is also important to note
rectly are possible in mice, and we describe their use to establish the clear emphasis of the HDFP report that “milder
that blood pressures are indeed altered by genetic changes in hypertension . . . bears the major burden of excess deathsAGT expression. Tests of differences in expression of the genes
attributable to elevated blood pressure.” Assessing thecoding for the angiotensin-converting enzyme (ACE) and for
cost versus benefit ratio of treating mild hypertensivethe natriuretic peptide receptor A are also considered, and we
provide a tabulation of all comparable experiments in mice. individuals is not a simple task, but there is little doubt
Computer simulations are presented that resolve the paradoxi- that a better understanding of the factors underlying the
cal finding that while ACE inhibitors are effective, genetic varia- incidence of the condition can be used to improve thistions in the expression of the ACE gene do not affect blood
ratio. The distribution illustrated in Figure 1 is boundpressure. We emphasize the usefulness of studying animals het-
to include individuals who have conditions alreadyerozygous for an inactivating mutation and a wild-type allele,
and briefly discuss a way of establishing causative links between known to cause hypertension, such as renal arterial ste-
complex phenotypes and single nucleotide polymorphisms. nosis or chronic renal failure, but the majority of individ-
uals who fall within the cross-hatched areas have high
blood pressures with no obvious cause—the definition
Our intention in this article is to present the logical of essential hypertension.
background that underlies studies aimed at understand- Determining the relative contribution of genetic and
ing how quantitative genetic variations influence blood environmental factors to the incidence of essential hy-
pressure. The starting point in this type of work is illus- pertension has not been easy. However, family studies,
such as those involving identical and nonidentical twins
raised in the same or in different environments, are con-
Key words: blood pressure, essential hypertension, genetic etiology, sistent in indicating, as Ward summarized, “that geneticcandidate gene, computerized gene simulation, ACE inhibitors, angio-
tensinogen. factors are primarily responsible for the observed familial
aggregation of blood pressure within populations. Over-
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Fig. 1. Frequency distribution of diastolic
blood pressures in 158,906 persons, 30 to 69
years of age. Redrawn with permission from
the progress report of the Hypertension De-
tection and Follow-Up Program [1].
In other words, one can transmit beneficial or harmful essential hypertension is the consequence of an unfortu-
nate combination of genetic variations that are not neces-“cultural factors” to one’s offspring as well as genes.
sarily the same in all of those affected and that individu-The simplest patterns of genetic transmission are those
ally may have only a modest effect on blood pressure.that in honor of their discoverer we now refer to as
Indeed, the distribution of blood pressures in most ofMendelian. Huntington’s chorea, for example, is inher-
the general population could well be just one particularited in a dominant Mendelian fashion, a defective gene
facet of the normal spectrum of human variability. Nev-received from either parent being sufficient to cause the
ertheless, it is important to recollect that minor geneticdisease, while cystic fibrosis is inherited as a Mendelian
differences, which may have been essentially neutralrecessive condition: Affected individuals must inherit a
when they first arose, may have noticeable consequencesdefective gene from each of their parents. Richard Lif-
in our modern society where individuals live well pastton, Bernard Rossier, and their associates have pion-
their reproductive period. Genetic variations that haveeered efforts to uncover families in which Mendelian
no deleterious effects in younger persons may provepatterns of inheritance are important in the control of
harmful in an older population.blood pressure. Glucocorticoid-remediable aldosteron-
ism (GRA) is an example of a dominant form of hyper-
tension caused by a genetic fusion of the regulatory se- CANDIDATE GENES
quences of 11b-hydroxylase with the coding sequence of A powerful method of uncovering genes of importance
aldosterone synthase [4], while mutations in the renal in determining a multifactorial trait is to first identify
chloride channel CLCNKB [5] account for one form of candidate genes by taking advantage of previous investi-
Bartter’s syndrome [6], a recessively inherited form of gations that have defined physiological variables and bio-
hypokalemic alkalosis with salt wastage and low blood chemical systems affecting the trait. One such system, in
pressure. However, these simply inherited Mendelian the case of blood pressure, is the renin-angiotensin sys-
forms of hypertension or hypotension are for the most tem. For a variety of reasons, including the fact that
part rare, as pointed out by Lifton in a 1996 summary: angiotensinogen (AGT) is at the head of this system,
“mutations in at least 10 genes have been shown to alter Jeunemaitre et al chose the AGT gene as a candidate
blood pressure; most . . . [in fact all but one, to which [8]. Going from an initial selection of a candidate gene
to proof that it is in fact important in determining thethis article will return] . . . are rare mutations” [7].
inheritance of hypertension can be accomplished by
demonstrating three things: (1) that the gene has variants
A HYPOTHESIS in human populations, (2) that the variants are inherited
What, then, is the genetic basis for the common forms in families along with (that is, cosegregate with) the
of essential hypertension? Our hypothesis, to which hypertensive trait, and (3) that the variants cause differ-
ences in blood pressure.many geneticists would probably also subscribe, is that
Smithies et al: Quantitative gene variations and hypertension 2267
As a first step toward this end, these investigators In practice, current knowledge of promoters is inade-
took advantage of a highly polymorphic simple sequence, quate to allow an a priori decision of what changes to
(GT)n, known to occur close to the AGT gene [9] and make in the sequence of a previously untested promoter
found that the hypertensive siblings in families with at to achieve a desired change. We therefore chose an alter-
least two affected siblings inherited the same simple se- native strategy to alter gene expression that is both uni-
quence variant more often than was expected by chance. versal in its applicability and predictable in its degree.
This demonstration of cosegregation of simple sequence
variants near the AGT gene with the hypertensive phe-
notype was sufficient to warrant looking for a possible GENE TITRATION
causative difference within the AGT gene itself. The
The strategy, which we call “gene titration,” is basedinvestigators therefore sequenced the coding exons and
on observations first made over 30 years ago by Harris,a short 59 noncoding region of the AGT genes from some
who summarized his findings with the statement: “Whereof their more hypertensive index cases and identified 15
. . . [a protein] is completely . . . absent in the affecteddistinct molecular variants. Comparing the frequencies
homozygotes, the values found in the heterozygotes areof the variants in the hypertensive index cases with those
usually about 50% of those found in normal homozy-in control normotensive siblings showed a significantly
gotes. Thus there often seems to be a simple gene dosagehigher frequency in the hypertensives compared with
relationship” [14]. This means that to obtain a half nor-the normotensives of one variant (threonine at position
235 instead of its alternative, methionine). An additional mal level of expression in a mouse one can use the het-
important observation was a significantly higher plasma erozygotes from a conventional gene knockout experi-
concentration of AGT in the 235T-bearing hypertensive ment, since they have only one functional gene in place
individuals, particularly women, than in individuals with of the usual two. The converse—how to obtain an in-
the 235M allele. crease in gene expression—is similarly presaged in the
These findings [genetic linkage of hypertension with genetic literature by Epstein’s compilation of data from
the (GT)n sequence, the identification of molecular vari- mice and humans who have three copies of a normal
ants of the AGT gene, differences in their frequencies gene, typically as a result of a chromosomal trisomy:
in hypertensive cases and controls, and a significant asso- “When gene products of 37 human and 7 mouse loci
ciation of plasma AGT concentrations with AGT geno-
were examined . . . the mean activities or concentrations
type] led the authors to hypothesize in suitably cautious
in trisomic cells were 1.61 6 0.25 (SD) and 1.55 6 0.10terms that “some molecular variants of angiotensinogen,
times normal (diploid) levels for the human and mouse”such as those identified or tagged by the variant at residue
[15]. How to replicate this situation deliberately is a little235, [may] lead to increased plasma or tissue angioten-
less obvious, but when targeting DNA is introduced insinogen. . . . This could lead to a slight overreactivity of
the form of a cut circle, the region of homology that isthe renin-angiotensin system.” However, proof that either
identical in the exogenous DNA and in the target genethe amino acid substitution and/or the difference in
ends up being duplicated. These two gene targeting tech-plasma AGT concentration caused changes in blood
niques—gene disruption and gene duplication—are sim-pressure was lacking.
ply related to each other topologically [16]. The same
DNA sequences can be used to obtain disruption of a
GENE TARGETING
gene or duplication of the same gene depending on how
Genetic studies in the mouse are, however, very effec- the sequences are assembled into a targeting construct
tive at testing causation. By using gene targeting [10], (Fig. 2) [17]. An additional genetic trick is required when
one can alter a gene in a predetermined manner and ask the gene to be duplicated is longer than can be accommo-
whether the imposed difference causes a change in the
dated into a practical targeting construct (as is usually
variable in question [11, 12]. Accordingly, our first plan
the case). Yeast geneticists have known for some timewas to change the amino acid at position 235 in mouse
that when sequences participating in homologous recom-AGT from methionine to threonine. The experiment
bination are incomplete, gap repair occurs during thewas short lived because mouse AGT does not have me-
recombination and supplies the missing portion by usingthionine at this position [13]. Indeed, this residue is
the target gene as a template [18]. This same phenome-poorly conserved in different species, suggesting that the
non occurs in mammalian cells during gene targetingspecific amino acid at position 235 is relatively unimpor-
[19]. Consequently, by using gene targeting in the twotant. Our second plan was therefore to alter the AGT
modes, we were able to generate a series of animalsgene in such a way that its level of expression would
in which the number of copies of the Agt gene varieschange. Theoretically, this should be possible by chang-
ing one or more nucleotides in the promoter of the gene. systematically [20].
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The significance of this conclusion with respect to hu-
mans is that it establishes in an animal model that modest
genetically determined differences in the Agt gene that
increase plasma AGT level by around 20% are sufficient
to alter blood pressure, albeit by only a few mm Hg. The
experiments should not be interpreted as suggesting that
gene disruptions and gene duplications (both of which
occur in humans, but are rare) contribute appreciably
to the etiology of essential hypertension. Rather, the
point is that small genetically determined differences in
AGT expression, regardless of how determined at the
DNA level, will affect blood pressure. It is therefore of
considerable interest that more recent work by Inoue
et al closes the circle in this particular argument, by
demonstrating two things: (1) that the 235 polymorphism
in the AGT gene is in tight linkage disequilibrium with
an additional, single nucleotide polymorphic difference
at position 26 in the promoter of the gene (G at 26
occurs almost exclusively with M at 235, while A at 26
occurs with T at 235), and (2) that the promoter with A
at 26 is stronger than the promoter with G at 26 [21].
Thus, there is a single nucleotide polymorphic difference
in the promoter of the T235 allele that can account for
the higher expression of the T235 allele and so, by infer-
ence from the mouse data, for an increase in blood pres-
sure. Published accounts of the effects on blood pressure
of the AGT gene polymorphism in humans are in general
agreement that modestly higher blood pressures accom-
pany the A-6 and T235 variant [22].
Fig. 2. Two modes of gene targeting: A, gene disruption and partial
HOMEOSTASISgene deletion; B, gene duplication. The top lines in the two parts of
the figure represent the target gene, ABCDEFGHIJ; the next lower A complicating feature in the study of the genetics
lines, the targeting constructs; the bottom lines, the modified genes.
of hypertension is the need for complex organisms toThe selectable marker gene is neo. The dashed lines have no length.
“Gap” indicates sequences missing in targeting construct B; they are maintain near constancy of their internal environments.
repaired during the recombination. Regions where homologous crossing This homeostasis is maintained by the operation of manyover occurs are shown by crosses. Note the different topological ar-
different but often interacting systems of considerablerangements of the same DNA fragments in the two targeting constructs.
sophistication that permit desirable physiological changes
in biological variables, but that also act homeostatically
if external factors cause undesirable changes in the vari-THE AGT GENE
ables. Such homeostatic adjustments in response to changesFigure 3A shows that the steady-state concentration
in external factors have been studied extensively in theof AGT in the plasma of the resulting animals increases
past. However, little attention has been given to a categori-progressively with gene copy number and includes the
cal different set of homeostatic adjustments that must berange observed by Jeunemaitre et al in their hypertensive
made. These are the adjustments needed to accommodatepatients (,120% of that in the normotensive siblings)
the endogenous genetic differences that distinguish one[8]. We measured the blood pressure of the animals
individual from another. Homeostatic adjustments of thisand found, as illustrated in Figure 3B, that the blood
category occur in our mouse experiments and illustratepressures of the one-copy through three-copy mice also
very well the difficulties that face investigators wishing toincreased progressively with the Agt gene copy number.
determine what genetic factors affect blood pressure. AA firm conclusion can be drawn from these experiments,
clue to the extent of this category of homeostasis can benamely that genetically determined changes in the level
seen in the steady-state plasma level of AGT in the miceof expression of the Agt gene directly cause changes in
with only one functional copy of the Agt gene instead ofthe blood pressure of mice, and that these changes are
the two copies present in the wild type; the level in theobservable in animals that are otherwise wild type and
have all their normal homeostatic mechanisms intact. one-copy animals is only 35% of normal, which is signifi-
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Fig. 3. Gene titration experiments in which
the number of copies of three genes are varied
and their effects on the amounts of encoded
protein product as percentage of wild type (left
panels) and on blood pressure (right panels)
are determined. (A) Plasma angiotensinogen
(AGT). (B) Blood pressures in AGT mice. (C)
Serum angiotensin-converting enzyme (ACE)
activities. (D) Blood pressures in ACE mice.
(E ) Guanylate cyclase activity of natriuretic
peptide receptor A (NPRA) in the lung in the
presence of excess atrial natriuretic peptide.
(F ) Blood pressures in NPRA mice. The pri-
mary sources of data are references [19, 22, 28].
cantly less than the expected 50% level. The cause of Some additional comments are required before closing
this discussion on homeostatic compensations induced bythis low steady-state plasma AGT level proves to be a
homeostatic increase in the number of cells producing allelic differences. The data accumulated by Epstein, to
which we referred initially [15], and our own experiencerenin in the kidney so that plasma renin levels are almost
250% normal [23]. However, despite this homeostatic in- with heterozygotes for disruption of many genes are in
agreement with Epstein’s summary statement that “con-crease in renin, the final result is a steady-state concentra-
tion of angiotensin II (Ang II) in the Agt one-copy mice trol mechanisms to regulate the final concentration of the
gene product at some fixed level do not exist.” [24] In otherstill significantly less than normal, as are their blood pres-
sures. Thus, in this instance, homeostatic changes reduce words, automatic up- or down-regulation of a gene to com-
pensate for any genetic disturbance in its own expressionbut do not abolish the effect on blood pressure of the
genetically induced change in Agt gene expression. or in that of its allelic partner does not occur. This does
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not mean that compensations by specialized homeostatic COMPUTER SIMULATIONS
systems have not been evolved, such as the changes in We therefore explored the possibility that the absence
renin production that we have discussed or repression of differences between the blood pressures in the mice
of the expression of cholesterol biosynthetic enzymes by with one through three copies of the Ace gene is due to
intake of dietary cholesterol [25], but it does mean that a different phenomenon, namely, the intermediate posi-
these homeostatic compensations are not an automatic tion of the ACE enzyme in a multistep pathway that can
property of genes. A significant corollary of this conclu- stabilize at different steady states depending on factors
sion is that the quantitative effects of allelic variants are that influence different parts of the system. Niederberger
strictly and algebraically additive so that, for example, if et al have published extensively on this general topic
a heterozygote inherits one allele causing 120% average [29], mainly in relationship to the net flux of substrates
and products through the multistep pathways leading toexpression, with a second causing 70%, the net expres-
the synthesis of essential metabolites such as argininesion will be 95%.
and tryptophan. From their theoretical treatment and
observations in their experiments they concluded that
THE ACE GENE increases of between 10-fold and 50-fold in the activities
of four enzymes that are intermediate in the tryptophanA second gene in the renin-angiotensin system that obvi-
synthetic pathway increased the total flux (that is, overallously merits attention as a candidate for affecting blood
synthesis) of tryptophan by at most 30%, while a fourfoldpressure is that coding for the angiotensin-converting
decrease in the activities of individual enzymes causedenzyme (ACE). In addition to the enzyme being a key
no more than a 25% decrease in total flux.element in the system, its gene is a candidate because
We approached the same type of problem in the renin-ACE inhibitors are such effective drugs for the treatment
angiotensin system with the help of a generally applica-of hypertension and because in humans a common poly-
ble set of programs for simulating the behavior of com-morphism in the gene is associated with a quantitative
plex interacting systems (STELLAt; High Performancedifference in the level of ACE in plasma [26]. Individuals
Systems Inc., Hanover, NH, USA). Figure 4 shows thehomozygous for the I allele (gene frequency 0.4) have
simplest model that yielded informative results with theplasma ACE concentrations of 300 mg/L; individuals ho-
endocrine arm of the renin-angiotensin system [30]. Fig-mozygous for the D allele (gene frequency 0.6) have 500
ure 4 is essentially a diagrammatic formalization of rela-mg/L. Heterozygotes have 400 mg/L. Accordingly, we
tionships between the genes, proteins, enzyme substrates,carried out a gene titration experiment with the Ace
and products of the system. The feedback loop betweengene [27]. Figure 3C shows that plasma ACE activities
blood pressure and renin production is not included inin the resulting mice vary progressively, with the activi-
this simplest model, nor do we include the role of ACE
ties of the one- and three-copy animals ranging from
in the destruction of the kinins. However, later in this
approximately 65 to 150% of wild type. Surprisingly,
article we see that the conclusions drawn from the simu-
however, as shown in Figure 3D, the blood pressures of lations are not affected by these simplifications. Table 1
the same animals are not affected by this nearly threefold lists some of the equations and constants that are re-
change in plasma ACE activities. This result is paradoxi- quired in modeling the dependence of the various com-
cal when one considers that ACE inhibitors lower blood ponents on each other. (A complete set is available from
pressure in mice [28] as they do in humans. us on request.) For example, equation 2 describes how
A possible explanation of the lack of effect of gene the change in concentration of an intermediate Q is de-
copy number on blood pressure might be that homeo- termined by the rate of formation of Q from its precursor
static compensations are sufficient to overcome the changes P minus the rate of conversion of Q to the product R
in the circulating ACE. However, the Ace one-copy mice and minus the rate of “clearance” of Q, where clearance
have the expected half normal levels of ACE mRNA in means loss through the kidney, destruction by other en-
their lungs (a major site of ACE synthesis) so that there zymes, etc. Equation 6 describes the rate of conversion
is no evidence of any homeostatic compensation in the of angiotensin I (Ang I) to angiotensin II (Ang II) and
expression of the remaining normal Ace gene in these assumes that this conversion is governed by Michaelis-
animals (our unpublished observations). A small but sig- Menten kinetics. Although precise values for many of
nificant increase in kidney renin mRNA, of the order of the variables and constants are not known, their relative
30%, does occur in the one-copy animals, but this seems values can be estimated. For example, it is quite certain
unlikely to account for their normal blood pressures, that the plasma concentration of Ang I (in the picomolar
since it is only about one third of the increase in kidney range) [31] is well below the Km of ACE (which is in the
renin seen in the Agt one-copy animals and they still micromolar range) [32], while the plasma concentration
of AGT is in the same range as the Km of renin [32–34].have below normal blood pressures.
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Fig. 4. The simplest representation of the en-
docrine arm of the renin-angiotensin system
that was informative in the computer simula-
tions with STELLAt.
However, because precise values of many of the relevant
constructs are not known, the numerical values resulting
from our simulations should not be interpreted literally.
Nevertheless, the relationships between the variables re-
Table 1. Chief equations and constants required for simulating the vealed by the simulations are robust because they are
renin-angiotensin system
relatively insensitive to the exact values assigned to the
Equations constants.
(1) Change of [Protein A]a 5 (Number of A genes3Rate of pro- We used the computer simulation to answer two ques-
ducing A per gene)2 (Inactivation rate of A) tions: Why does a genetically determined threefold varia-
(2) Change of [Intermediate Q]5 (Rate of P to Q)2 (Rate of Q
tion in AGT production alter blood pressure, while anto R)2 (Clearance rate of Q)
(3) Inactivation rate of A5 [Protein A]3 Inactivation constant exactly comparable change in ACE production does not?
for A Why do ACE inhibitors affect blood pressure, while
(4) Clearance rate of Q5 [Intermediate Q]3Clearance constant
genetically halving ACE levels has essentially no effect?for Q
(5) AGT!Ang I5 [AGT]3[Renin]3Renin kcat/([AGT]1Renin Figure 5A and B illustrate simulations that help an-
Km) swer the first question. Figure 5A shows the simulated
(6) Ang I!Ang II 5 [Ang I]3 [ACE] 3ACE kcat/([Ang I]1
plasma levels of Ang I and Ang II when the number ofACE Km)
Constants for which values must be chosen Agt genes is varied from one through three, but the
Km and kcat for renin and ACE number of Ace genes is the normal, two. Figure 5B shows
Inactivation constants for AGT, Renin and ACE
the simulated levels when the number of Ace genes isClearance constants for Ang I and Ang II
varied, but the number of Agt genes is kept constant at
a Square brackets 5 concentration two. All parameters other than gene numbers are identi-
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Fig. 5. Computer simulations of the angiotensin I (dotted line) and angiotensin II (solid line) concentrations when the following occurs: (A) the
number of copies of the AGT gene is varied; (B) the number of copies of the ACE gene is varied; (C ) the extent of inhibition of ACE with a
converting enzyme inhibitor is varied. The scales in C are logarithmic. The arrows in C depict the region where Ang II levels are sensitive to
further increases in the extent of ACE inhibition. Other details of the simulations are described in [24].
cal in these two simulations. The results are clear and in Ace one-copy mice), an increase in Ang I concentration
offsets the decrease in ACE activity so that Ang II con-agreement with the genetic experiments: A progressive
increase in Agt gene copy number yields a progressive centrations remain essentially constant. However, Ang I
concentrations cannot increase indefinitely; they eventu-increase in both Ang I and Ang II levels (the latter being
equated to blood pressure in this simulation), while the ally plateau when “clearance” of Ang I by loss through
the kidney and/or by degradative pathways account forsame range of increase in Ace gene number has virtually
no effect on Ang II levels, although it has a marked the majority of its production. Once this Ang I plateau is
reached, further decreases in ACE activity are no longereffect on Ang I.
The ability of the simulation to replicate the experi- offset, and thus a decrease in Ang II, and thence of
blood pressure, ensues. Note that the increases in Ang Imental observations is satisfying and a necessary prereq-
uisite before any credence can be put on the procedure, concentration induced by the genetic changes in expres-
sion of either the AGT or the ACE gene (Fig. 5A, B)but its chief value is in leading to a clearer understanding
of the underlying relationships. In the present case, these are up to about two times normal, while the increase
induced by ACE inhibition is to about 20 times normalrelationships were most easily conceptualized by consid-
ering the one-copy animals in which either AGT or ACE (the scales in Fig. 5C are logarithmic). The implication
of this difference is that the genetically induced changesis less than normal. When AGT decreases, the produc-
tion of Ang I decreases, which, when ACE is constant, are insufficient to move the system into the region where
ACE differences have an effect.leads to a parallel decrease in Ang II and so in blood
pressure. When ACE decreases, the conversion of Ang Space does not permit a detailed description of addi-
tional simulations that include the feedback inductionI to Ang II decreases, which, because Ang I production
has not been changed, causes an increase in the steady- of increases in renin production caused by decreases in
blood pressure or by ACE inhibition and the effects ofstate plasma concentration of Ang I, which offsets the
effects of the decrease in ACE activity so that Ang II ACE on bradykinin concentrations. However, their bear-
ing on the present topic can be summarized by notingproduction and blood pressure are virtually unaffected.
An answer to the second question—why ACE inhibi- that increased renin production induced by a decrease
in blood pressure acts homeostatically to increase Ang Itors reduce blood pressure when a genetically induced
half normal level of ACE does not—required extending and Ang II concentrations, and so tends to restore blood
pressures. In contrast, increased renin production in-the simulation to consider more severe decreases in ACE
activity. The results are most easily presented (Fig. 5C) duced by ACE inhibition has virtually no effect on Ang II
concentrations; its effects are on Ang I concentrations.as a plot of Ang I and Ang II levels against the inhibition
of ACE, with the simulation using exactly the same pa- Other simulations that include bradykinin and its inacti-
vation by ACE show that the plasma level of this peptiderameters as in the two previous examples except that
the decrease in ACE activity now covers a wider range is inversely affected by changes in the level of ACE;
these effects are not offset by secondary changes. The(9% inhibition, 90%, 99%, etc.), and both axes of the
graph are now logarithmic to accommodate this wide relative importance of Ang II and bradykinin in the con-
trol of blood pressure is not predictable by simulations ofrange. The result is again clear: At low extents of ACE
inhibition (including the 50% level equivalent to the this type. However, the absence of a decrease in blood
Smithies et al: Quantitative gene variations and hypertension 2273
pressure in mice with half normal levels of ACE suggests opposite direction. The natriuretic peptides, atrial natri-
uretic peptide and brain natriuretic peptide, are synthe-that its effects in this context are not important. Whether
this is the case in humans is still a matter of debate. sized primarily in the heart, where their expression is
stimulated by factors that stretch cardiac muscle [37].Thus, in humans, there is no consensus regarding the
effects on blood pressure of the genetic variations in Three receptors implement their downstream function,
of which the one most directly related to blood pressureACE levels associated with the I/D polymorphism [35].
The diversity in the human data may be caused by differ- is the guanyl cyclase natriuretic peptide receptor A
(NPRA), the product in the mouse of the gene Npr1. Aences in the genetic backgrounds of the several study
populations and/or by the effects of differences in dietary gene titration experiment with the Npr1 gene is illus-
trated in Figure 3E in which the linear relationship be-salt intake on the kallikrein-kinin arm of the system.
Three firm conclusions follow from the mouse genetic tween gene copy number and gene expression is particu-
larly well demonstrated [38]. Once more, the bloodexperiments and the accompanying simulations: first,
modest genetically-induced changes in expression of the pressures of the resulting animals (Fig. 3F) are affected
by quantitative differences in expression of the gene,Agt gene directly and proportionately affect plasma Ang
II concentrations and blood pressure. Second, similar although in this case, in the opposite sense from the Agt
gene. Npr1 is therefore another gene for which quantita-changes in expression of the Ace gene do not affect Ang
II concentrations or blood pressure because they are tive variations affect blood pressure.
An important caveat is necessary, however. Proof byoffset by unavoidable concomitant changes in Ang I con-
centrations, although bradykinin concentrations are af- mouse experiments that quantitative changes in expres-
sion of Npr1 (or any other gene) affect blood pressure orfected by these changes in Ace gene expression, and
third, the major effects of ACE inhibitors on Ang II its homeostasis make a strong argument that comparable
changes in humans are also likely to influence bloodconcentrations (and hence blood pressure) do not com-
mence until a threshold is reached beyond which changes pressure. However, the circle is not closed until variants
of the candidate gene are proven to occur in humanin the concentration of Ang I no longer occur, with the
result that further progressive inhibition of the enzyme populations and are demonstrated experimentally to
have similar effects on the expression of the gene or theby the drug is effective in changing the concentration of
Ang II and blood pressure. function of its product. Such studies have not yet been
done with the NPRA gene in humans.Experimental validation of the first conclusion with
respect to the general effects of a half-normal expression
of the Agt gene has been published. Both Ang I and HETEROZYGOTES
Ang II plasma concentrations decrease by approximately
An important distinction exists between experiments50% [19]. Our unpublished observations validate the
to investigate the effects of quantitative changes in genereverse situation: increased expression of the Agt gene
expression from those that investigate the effects of ab-causes a comparable increase in the plasma levels of
sence of gene function. The latter, which include conven-both peptides. The second conclusion is validated by our
tional gene knockout experiments, are often more quali-unpublished finding that in the Ace one-copy animals,
tative than quantitative. Nevertheless, the heterozygotesAng I concentrations in plasma are increased by almost
generated in the course of a conventional gene knockout50%, but Ang II concentrations are unaffected. Bradyki-
experiment are, with a few exceptions such as when anin concentrations in the Ace one-copy animals are in-
gene is X-linked or is subject to imprinting, half of acreased by 20%, as predicted qualitatively by the simula-
quantitative gene titration experiment and, as such, cantions. The validity of the third conclusion has already
provide a wealth of quantitative information. Unfortu-been very well documented by Campbell, Kladis, and
nately, this information is largely untapped because onlyDuncan in an extensive study in rats of the effects of a
a small proportion of investigators study their heterozy-wide range of doses of the ACE inhibitor perindrol; the
gotes in detail, for the obvious reasons that the homozy-authors found that “when Ang I levels were unable to
gotes are more dramatic and the phenotype of the het-increase further, higher perindrol doses caused plasma
erozygotes is often subtle and easily overlooked.Ang II levels to fall” [36].
Failure to detect any change in blood pressure or any
other phenotype of interest in heterozygous null animals
THE NATRIURETIC PEPTIDE SYSTEM should be accepted with caution when the homozygous
null animals have a marked phenotype. In some cases,The renin-angiotensin system is by no means unique
with respect to the effects that genetically determined as with the Ace gene one-copy animals, the apparent
absence of a heterozygous phenotype can lead to a betterchanges in quantitative gene expression have on blood
pressure. For instance, the natriuretic peptide system has understanding of the overall system. Indications are that
this may also apply to our recent work with the genecomparable effects, although in general it acts in the
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Table 2. Effects on renal functions of NKCC2 genotype the absence of a direct effect of modest changes in the
expression of a gene does not extrapolate to an absenceNKCC2 genotype
of relevance to hypertension and its treatment, even1/1 1/2 2/2
though it decreases considerably the likelihood that such
NKCC2 protein 10067 5468 060a
changes contribute to the etiology of essential hyperten-% wild-type
Urine volume 1.660.2 1.660.3 10.060.9a sion. To help summarize the overall situation, we have
mL/day/20 g body weight therefore compiled in Table 3 a list of genes and related
Urine osmolality 2300670 2350665 371620a
transgenes in which the effects on blood pressure inmOsm
Plasma renin concentration 23.564.5 23.565.0 751676a mice have been reported. The relevant data from all the
ng Ang I/mL/hr publications that we have found are tabulated as the
a P , 0.0001 versus 1/1 and 1/2 differences from wild type in the blood pressures of ani-
mals either having zero, one, or three copies of the nor-
mal wild-type gene or having a transgene. Wild-type
pressures are presented but should be interpreted withcoding for the kidney-specific sodium potassium chloride
caution, since they are more sensitive than the differ-cotransporter NKCC2. Loss of function mutations in
ences to variations in the procedure for measuring pres-this gene in humans [39], like CLCNKB, cause Bartter’s
sures. In some instances, homeostatic changes have beensyndrome. Mice homozygous for inactivation of the
reported that tend to restore pressures to normal; theNKCC2 gene exhibit severe polyuria and dehydration
corresponding pressure differences are given a super-and die before weaning; a small proportion (,10%) of
script h. Their significance may be greater than suggestedthe homozygotes survive if treated with indomethacin
by the numerical value of the difference. To help theshortly after birth, although the survivors have severe
reader identify genes relevant to the genetic control ofhydronephrosis [40]. Heterozygous mice, with one func-
basal blood pressures in mice and therefore to the genetictional copy of the NKCC2 gene, express only half of the
etiology of hypertension, the bold type in Table 3 high-normal amounts of the cotransporter in their kidneys.
lights those genes for which modest changes in expres-However, they have no detectable disturbances in their
sion affect blood pressure. Underlined genes are thoseability to concentrate urine or in their plasma renin con-
for which modest changes in expression do not affectcentrations, despite the fact that both of these features
blood pressure in mice. Genes neither bolded nor under-show extreme abnormalities in the homozygous null ani-
lined have either not been tested quantitatively or themals (Table 2).
current data are inconclusive. Even with these relativelyFurosemide and bumetanide are two inhibitors of the
restrictive criteria for acceptance, Table 3 includes 10NKCC2 cotransporter that are used in patients to control
genes that are strong candidates for being involved intotal body fluids and reduce blood pressure [41]. Admin-
the etiology of essential hypertension. A greater numberistering furosemide to wild-type mice replicates most
merit further work before they can be excluded. The quan-of the disturbances of the null homozygotes [40]. The
titative information that is readily accessible through thesituation is consequently very similar to the paradox
study of animals heterozygous for a gene knockout sug-encountered in the Ace gene experiments vis a` vis the
gests an exhortation to those engaged in this type of work:efficacy of ACE inhibitors, namely that a genetically
“Treasure your heterozygotes.”induced 50% decrease in the expression of the gene has
no obvious effects, but a drug that inhibits the gene
product is nonetheless effective. Because the computer SINGLE NUCLEOTIDE POLYMORPHISMS
simulations of the renin-angiotensin system resolved the
Single nucleotide polymorphisms (SNPs) are the mostparadox with ACE, we are embarking on a similar en-
common form of genetic variability in human popula-deavor to model ion transport and ion balances within
tions, and they occur within both coding and noncodingand around a simplified representation of the cells in the
regions of genes. SNPs leading to differences in codedthick ascending limb of the loop of Henle and in the
amino acids are obvious candidates for altering proteinmacula densa where NKCC2 is expressed. Our aim is to
function. SNPs in the noncoding regions close to codingdetermine why the decrease in NKCC2 to 50% has no
sequences are candidates for altering gene expression.effect, when the drug has such marked effects.
Determining which of them actually cause differences
in gene function or gene expression will not be easy.
OVERALL STATUS One approach is to replace the equivalent endogenous
mouse gene with each of the human allelic variants andIn the foregoing, we presented data demonstrating
then investigate the phenotypes of the “humanized”that modest changes in the expression of two genes (Agt
mice. This procedure has already been successful in prov-and Npr1) affect blood pressure in mice, while changes
in a third (Ace) do not. However, we have also seen that ing that the two amino acid sequence differences that
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Table 3. Genes tested for their effects on blood pressure in mice
0 copy 1 copy 3 copy Transgenic
Wild-type
Gene Common name DBP BP DBP Reference
Adra3 adenosin A3 R 21 117 [44]
Ace 233 25 116 [28]
11h 117 22 [27]
Adm adrenomedullin 24 112 12 KMC
Adora2a adenosinA2aR 120 117 [45]
Adra1b a1b adrenergic R 0 119 [46]
Adra2a a2a adrenergic R 13 128 [47]
Adra2b a2b adrenergic R 0 118 [48]
Adra2c a2c adrenergic R 0 138 [48]
Adrb2 b2 adrenergic R 0 114 [49]
Agt 216h 28h 130 18 [20, 23]
Agtr1a AT1aR 222h 210 108 [50]
243h 217h 133 [51, 52]HSK
Agtr1b AT1bR 21 101 [53]
29 123 [54]
Agtr2 AT2R 117 102 [55]
14 122 [56]
Ann6 annexin 0 105 [57]
Apoe apolipoprotein E 116 110 [58]
Arrb1 barrestin 1 14 114 [59]
Avp vasopressin 122 222 [60]
Bdkrb2 bradykininB2R 115 12 109 [61]
134(HS) 114(HS) 115(HS) [61]
17 11 114 [62]




Brs3 bombesin R3 11 110(4m) [66]
115 116(10m) [66]
Cgrpa calcitonin gene- 15 129 [67]
related peptide 121 118 [68]
Cnr1 cannabinoid R 110 113 [69]
Crhr2 CRHR 110 88 [70]
Drd1 dopamineD1R 120 123 84 [71]
Drd3 dopamineD3R 123 120 97 [72]
Edn1 ET1 111 105 [73]
88 22 [74]
Ednra ETAR 15 125 [75]
Ednrb ETBR 115(2/s) 22(1/s) 110 [75]
Fgf2 FGF2 221 0 99 [76]
Gh growth hormone 88 0 [77]
Glut4 136 102 [78]
Hsd11b2 11bHSD2 125h 27 121 [79]
Irs1 111 99 [80]
Klk kallikrein 101 222 [81]
Klkbp kallikrein binding 101 212 [82]
protein
Ldlr LDL R 143 111 [83]
Mme NEP 223 121 [84]
Nos1 nNOS 25 95 [85]
Nos2 iNOS 22 21 116 [86]
Nos3 eNOS 120 97 [87]
118 14 122 [86]
99 218 [88]




Nppb BNP 125 225 [92]
23 25 121 [93]
21(HS) 22(HS) 118(HS) [93]
Npr1 GC-A 120 18 77 [94]
NPRA 116 136 [95]
19 123 25 [38]
Npr3 NPRC 29 21 119 [96]
(continued)
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Table 3. (Continued)
0 copy 1 copy 3 copy Transgenic
Wild-type
Gene Common name DBP BP DBP Reference
Npy2r NPY Y2R 211 117 [97]
Lep Ob 214 106 [98]
Ptgerep1 EP1 0 98 [99]




Ptgerep3 EP3 21 120 [99]
Ptgerep4 EP4 17 101 [99]
Ptgir PGI2R 23 85 [102]
Ptgs1 COX1 12 0 122 SGM
28(LS) 101(LS) TMC
Pthrp1 PTHrP 135 214 [103]
Pth1r PTH/PTHrPR 133 216 [104]
Ren 1c 228 23 86 [105]
Ren 1d 22(M) 21(M) 94(M) [106]
213(F) 28(F) 94(F) [106]
Ren 2 21 11 85 [107]
Scnn1b bENaC 18 130 [108]
28(LS) 130(LS) [108]
Serca3 SR Ca 11 78 [109]
ATPase 3
Slc12a1 NKCC2/BSC1 11 114 NT
Slc12a2 NKCC1/BSC2 223 214 92 [110]
28 108 [111]
Slc12a3 TSC 22h 87 [112]
214(LS) 86(LS) [112]
Slc9a1 NHE1 99(HS) 121(HS) [113]
Slc9a3 NHE3 29 12 92 [114]
Tbxa2r TXR 17 93 [115]
Bold italics indicates genes for which quantitative differences in expression have been demonstrated to affect blood pressure. Underlined italics indicates genes
for which quantitative differences in expression do not affect blood pressure. Italics (not bold or underlined) indicate genes for which quantitative differences in
expression have not been made or are inconclusive. Methods of BP measurements differ in various experiments. As much as possible, the listed values are mean
BP. Where investigators report more than one set of BP measurements, we have selected one that appears most representative. Where a difference between sexes
has been reported, the sexes are distinguished. Homeostatic adjustments have been demonstrated where indicated by a superscript h. Personal communications are
from: KMC, Kathleen M. Caron; TMC, Thomas M. Coffman; HSK, Hyung-Suk Kim; SGM, Scott M. Morham; NT, Nobuyuki Takahashi. Abbreviations are: F,
female; HS, high salt; LS, low salt; m, month; M, male; S, piebald mutation.
characterize three common alleles of the human apolipo- genetic background in the animals involved [43]. Back-
crossing to a constant inbred background before makingprotein E gene result in readily distinguishable effects
on atherogenesis in mice [42]. Analogous experiments the combinations is one possible approach. Combining
mutants that were generated and maintained within awith human allelic variants, coding or noncoding, that
may be found in genes demonstrated to influence blood single already inbred strain is another possibility. An-
swering the question of whether small variations in dif-pressure or its homeostasis in mice should be equally
informative, although care will be needed in instances ferent genes have simple additive effects on blood pres-
sure must await completion of these experiments.in which the protein under test interacts with other pro-
teins or receptors that have species-specific properties.
CONCLUDING REMARKS
COMBINATIONS OF VARIANTS This article has developed the thesis that quantitative
differences in the expression of many genes can affectA formidable task still remains for experimental ge-
neticists who study mice and humans: to test and sort blood pressure in mice and, by inference, in humans with
all of their normal homeostatic processes intact. Severalout the effects on blood pressure of combinations of
genetic variations both within systems (such as two vari- implications of this thesis merit comment with respect
to the present status and future prospects of diagnosingants within the renin-angiotensin system) and between
systems (such as one variant in the renin-angiotensin and treating essential hypertension. The chief tool for
diagnosis is still the sphygmomanometer, which in a verysystem combined with another variant in the natriuretic
peptide system). The chief difficulty facing this type of real sense only estimates the difference between those
genetic and environmental factors that tend to increaseinvestigation in mice is the need to ensure a constant
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tide repeat polymorphism in the human angiotensinogen gene.blood pressure and those that tend to decrease it. Be-
Nucleic Acids Res 19:6978, 1991
cause physicians currently have no means of uncovering 10. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherla-
the discrete factors underlying essential hypertension, pati RS: Insertion of DNA sequences into the human chromo-
somal beta-globin locus by homologous recombination. Naturedetermination of the most suitable drugs and doses for
317:230–234, 1985each patient is largely empiric. If the starting hypothesis 11. Thomas KR, Capecchi MR: Site-directed mutagenesis by gene
of this perspectives has any validity, and the mouse ex- targeting in mouse embryo-derived stem cells. Cell 51:503–512,
1987periments suggest that it does, then the future can be
12. Doetschman T, Gregg RG, Maeda N, Hooper ML, Meltonviewed optimistically. Once a tally, even if incomplete, DW, Thompson S, Smithies O: Targeted correction of a mutant
has been made of the genes whose expression affects HPRT gene in mouse embryonic stem cells. Nature 330:576–578,
1987blood pressure, a new generation of diagnostic tools can
13. Clouston WM, Evans BA, Haralambidis J, Richards RI: Mo-be designed. Basic scientific and clinical data should lecular cloning of the mouse angiotensinogen gene. Genomics
eventually tell us which of the alleles of the tallied genes 2:240–248, 1988
14. Harris H: The Principles of Human Biochemical Genetics. Neware potentially protective and which are damaging. This
York, American Elsevier Publishing Company Inc., 1970information should enable the design of DNA micro-
15. Epstein CJ: Down Syndrome (Trisomy 21), in The Metabolic
chips of relatively modest complexity to determine which Basis of Inherited Disease (vol 1, 6th ed), edited by Scriver CR,
Beaudet AR, Sly WS, Valle D, New York, McGraw-Hill, 1989,alleles are present in a given patient. The net result can
pp 291–326be the selection of treatments tailored to the specific
16. Gregg RG, Smithies O: Targeted modification of human chromo-
individual, thereby exposing fewer persons to side- somal genes. Cold Spring Harb Symp Quant Biol 51:1093–1099,
1986effects from treatments that are less than optimal.
17. Smithies O, Kim HS: Targeted gene duplication and disruption
for analyzing quantitative genetic traits in mice. Proc Natl Acad
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